Cancer staging is the process of measuring how much cancer is present in the body and where it has spread. When your oncologist says “Stage II breast cancer” or “T3 N1 M0,” they are describing the same thing in two different levels of detail — and both pieces of information directly determine which treatment you will receive, what your prognosis is, and whether a clinical trial is open to you.
Cancer staging matters because cancer is not one disease — it is hundreds of diseases that behave very differently depending on extent. A Stage I lung cancer treated with surgery has a 5-year survival rate above 90%. A Stage IV lung cancer has a 5-year survival below 10%. Treatment choice, radiation fields, chemotherapy regimens, and surgical approach all follow directly from stage. For context on the tests that determine stage — imaging and biopsy — see our guides to imaging tests for cancer and biopsy for cancer.
The TNM System — What T, N, and M Mean
The TNM staging system — published by the American Joint Committee on Cancer (AJCC) and the UICC — is the international standard for staging virtually all solid tumors. The current edition is the AJCC 8th edition, effective January 2018. TNM describes cancer along three dimensions:
T — Primary Tumor
| T Category | Meaning |
|---|---|
| TX | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma in situ — cancer cells present but no invasion through the basement membrane |
| T1 | Smallest primary tumors — specific size/extent varies by cancer type |
| T2 | Intermediate size or local invasion |
| T3 | Larger size or greater local invasion |
| T4 | Largest or most invasive — often involves adjacent organs or critical structures |
T criteria are site-specific. For breast cancer, T1 = ≤2 cm; T4 = chest wall or skin involvement. For lung cancer, T1 = ≤3 cm; T4 = mediastinal invasion. You cannot compare T3 in one cancer to T3 in another — the measurement is defined separately for each anatomic site.
N — Regional Lymph Nodes
N describes whether cancer has spread to regional lymph nodes. N0 = no nodal involvement; N1–N3 = increasing number or extent. Pathologically confirming N staging requires sentinel lymph node biopsy (SLNB) or lymph node dissection — imaging-based clinical N staging underestimates involvement in approximately 15–30% of cases.
M — Distant Metastasis
M0 = no distant metastasis. M1 = distant metastasis confirmed. This is the simplest and most consequential component. In some cancers (melanoma, lung, renal cell), M is substratified by metastasis location: in melanoma, M1a = skin/soft tissue; M1b = lung; M1c = visceral organs; M1d = brain/leptomeningeal.
Stage I Through IV — What Each Stage Means
TNM values combine into overall stage groups I through IV. Using breast cancer as an example of how TNM maps to stage:
| Stage | TNM Example (Breast Cancer) | Approximate Meaning |
|---|---|---|
| 0 | Tis N0 M0 | DCIS — non-invasive; cancer cells present but confined, no invasion |
| I | T1 N0 M0 | Tumor ≤2 cm; no lymph node involvement; no metastasis |
| IIA | T2 N0 M0 or T1 N1 M0 | 2–5 cm tumor with no nodes, or ≤2 cm tumor with 1–3 positive nodes |
| IIB | T2 N1 M0 or T3 N0 M0 | Larger tumor or limited positive nodes + moderate-size tumor |
| IIIA | T3 N1 M0 or any T N2 M0 | Extensive nodal involvement or large tumor |
| IIIC | Any T N3 M0 | ≥10 positive nodes or infraclavicular/internal mammary nodes |
| IV | Any T, Any N, M1 | Cancer spread to distant organs (liver, lungs, bone, brain) |
What each stage means practically:
- Stage I: Localized and small; curative treatment usually possible; 5-year survival typically >90% for most cancers
- Stage II: Larger tumor or limited nodal spread; often curable with surgery + systemic therapy; chemotherapy commonly added to treat micrometastatic disease not yet visible on imaging
- Stage III: Extensive local disease or significant nodal involvement, no distant spread; requires multimodality treatment (surgery + chemotherapy + radiation); long-term cure is possible
- Stage IV: Distant metastasis confirmed; treatment goals typically shift toward disease control and quality of life — but Stage IV is not uniformly terminal (see survival section below)
Clinical vs. Pathological Staging
Clinical staging (cTNM) is performed before treatment using imaging (CT, PET-CT, MRI), physical examination, biopsy, and endoscopy. It is necessary for treatment planning but is less accurate than pathological staging.
Pathological staging (pTNM) is determined after surgery when a pathologist examines the removed primary tumor and lymph nodes — measuring exact dimensions, assessing margins, and counting positive nodes. This is the gold standard for prognosis and trial comparisons.
The gap matters: clinical N0 (no nodes on imaging) → pathological N1 (positive node found at SLNB) occurs in 15–30% of patients — upstaging that changes adjuvant therapy recommendations. This is precisely why sentinel lymph node biopsy provides pathological N staging for breast cancer and melanoma.
Staging for Specific Cancer Types
Breast Cancer
AJCC 8th added biological factors — creating “prognostic stage” alongside anatomic TNM. Stage grouping now integrates ER/PR/HER2 status, tumor grade, and Oncotype DX recurrence score. A ER-positive, HER2-negative, Grade 1 tumor has better prognosis than the same anatomic stage with triple-negative biology.
Lung Cancer
Stage IA1–IA3 (T1a–T1c, N0): 5-year survival 77–92% with surgery alone. Stage IIIA–IIIC: N2 (ipsilateral mediastinal nodes) or N3 (contralateral) — multimodality treatment required. Stage IV: 5-year survival <10% historically, but now 16–45%+ for EGFR/ALK/ROS1-mutated tumors with targeted therapy. Small cell lung cancer uses “limited stage” (one hemithorax) vs. “extensive stage” (beyond one hemithorax).
Colorectal Cancer
Stage I (T1–T2, N0): tumor confined to bowel wall layers. Stage II (T3–T4, N0): through the wall, no nodes. Stage III: positive lymph nodes. Stage IV: distant metastasis — most commonly to the liver. Critically, some Stage IV colorectal cancer is treated with curative intent: resectable liver-only metastases followed by surgical resection of primary and liver mets achieves 25–40% 5-year survival.
Prostate Cancer — NCCN Risk Groups
AJCC TNM staging alone is insufficient for prostate cancer management. NCCN risk stratification integrates PSA level, Grade Group (1–5, based on Gleason score), and clinical T stage into seven categories: very low → low → intermediate (favorable/unfavorable) → high → very high → regional (N1) → metastatic (M1). Treatment intensity follows risk group, not TNM alone.
Lymphoma — Ann Arbor / Lugano Classification
Lymphoma uses Ann Arbor staging (updated as Lugano 2014 with PET-CT integration): Stage I (single region), II (same side of diaphragm), III (both sides), IV (diffuse extralymphatic). Suffix B = B symptoms: fever >38°C, drenching night sweats, weight loss >10% body weight in 6 months — indicating more aggressive biology.
Gynecological Cancers — FIGO Staging
Cervical, endometrial, and ovarian cancers use FIGO (International Federation of Gynecology and Obstetrics) staging. Ovarian cancer FIGO staging is based on surgical-pathological findings at the time of surgery.
How Cancer Staging Is Determined
| Staging Component | Tests Used |
|---|---|
| T (local extent) | CT, MRI, endoscopy, physical examination, surgical pathology |
| N (lymph nodes) | CT (clinical), PET-CT (metabolic), MRI (pelvic nodes), SLNB or lymph node dissection (pathological) |
| M (distant metastasis) | CT chest-abdomen-pelvis (standard), PET-CT (lymphoma/lung/melanoma), bone scan (prostate/breast), brain MRI (lung/melanoma/breast) |
| Confirmatory biopsy | Confirms suspicious lymph node or organ involvement when imaging is equivocal |
Tumor markers from cancer blood tests — CEA, CA-125, AFP, LDH — supplement imaging but do not directly determine T, N, or M. CT scan is the most commonly used staging test for most solid tumors — a chest-abdomen-pelvis CT identifies primary tumor, suspicious nodes, and common distant metastasis sites in a single examination. See our CT scan for cancer guide for how CT staging is performed.
Stage and Survival — What the Numbers Mean (and Don’t Mean)
SEER (Surveillance, Epidemiology, and End Results) data from the NCI provides 5-year relative survival rates by stage — the most commonly cited statistics in cancer medicine.
| Cancer | Localized | Regional | Distant |
|---|---|---|---|
| Breast | 99% | 86% | 31% |
| Colorectal | 91% | 72% | 13% |
| Lung | 65% | 35% | 7% |
| Prostate | 100% (local/regional) | — | 37% |
| Melanoma | 99% | 72% | 35% |
| Ovarian | 94% | 75% | 31% |
| Pancreatic | 44% | 15% | 3% |
- They are population averages from historical cohorts — not predictions for your individual case
- They reflect treatment from 5+ years ago — they don’t capture recent advances in immunotherapy and targeted therapy (melanoma Stage IV 5-year survival improved from <5% to ~35% with checkpoint inhibitors; EGFR-mutant lung cancer Stage IV now has 20–30%+ 5-year survival with targeted therapy)
- Stage IV is not uniformly terminal: testicular cancer >95% cure rate at Stage IV; Hodgkin lymphoma Stage IV >90% 5-year survival; some colorectal Stage IV with liver-only mets: 25–40% 5-year survival after resection
- Cancer stages don’t “go backwards” — recurrence after Stage I treatment is documented as recurrent disease, not downgraded to Stage I
Frequently Asked Questions
What does Stage 1, 2, 3, and 4 cancer mean?
Stage I means the cancer is localized to the organ of origin, typically small, with no lymph node or distant organ involvement — curative treatment is usually possible. Stage II means a larger tumor or limited regional lymph node involvement. Stage III means extensive local invasion or significant lymph node involvement without distant spread — aggressive multimodality treatment is needed but cure is possible. Stage IV means cancer has spread to distant organs (liver, lungs, bone, brain) — treatment goals typically shift toward disease control, though some Stage IV cancers (testicular, Hodgkin lymphoma, select colorectal) are cured with standard treatment. According to the National Cancer Institute, cancer staging is the most important factor in determining treatment options for most solid cancers.
Is Stage 4 cancer always terminal?
No. While Stage IV means confirmed distant metastasis, outcomes vary enormously by cancer type and molecular biology. Testicular cancer at Stage IV is cured in over 95% of cases with cisplatin-based chemotherapy. Hodgkin lymphoma Stage IV has >90% 5-year survival with ABVD-based regimens. Some patients with colorectal cancer and liver-limited metastases achieve 25–40% 5-year survival after surgical resection of both the primary tumor and liver metastases. For solid tumors like pancreatic cancer, Stage IV prognosis is generally poor — but immunotherapy and targeted therapy have substantially improved outcomes for specific molecular subsets. Stage IV means treatment strategy changes; it does not mean treatment is futile.
How is cancer staging determined?
Staging combines imaging, biopsy, and sometimes surgical exploration. CT scan (chest-abdomen-pelvis with contrast) is the most common staging test for most solid tumors — identifying tumor size, lymph node involvement, and common metastatic sites in a single examination. PET-CT is the standard for lymphoma, lung cancer, esophageal cancer, and melanoma. MRI is used for brain, prostate, and rectal cancer staging. Sentinel lymph node biopsy provides pathological N staging for breast cancer and melanoma. Blood tests — CEA, CA-125, AFP, PSA — supplement imaging. See our guide to imaging tests for cancer for how each modality contributes to staging.
What is the difference between clinical and pathological staging?
Clinical staging (cTNM) is performed before treatment using imaging and biopsy — it estimates disease extent without directly examining the removed tumor or lymph nodes. Pathological staging (pTNM) is determined after surgery when a pathologist examines the removed specimen under a microscope — measuring exact dimensions, counting positive nodes, and assessing margins. Pathological staging is more accurate — studies show upstaging (finding more disease than imaging suggested) in approximately 15–30% of cases, particularly for lymph node involvement. Treatment recommendations — especially whether to add adjuvant chemotherapy — often depend on pathological findings.
Can cancer stage change over time?
Cancer stages describe disease extent at a specific point in time and do not change retroactively. If a Stage I cancer returns after treatment, the recurrence is documented as “recurrent disease” — not reclassified as Stage I. If cancer spreads during treatment, the new extent is documented with prefix “r” (rTNM for recurrence staging) or “y” (ypTNM for post-neoadjuvant staging). Cancer does not “improve” from Stage IV to Stage III even if treatment dramatically reduces tumor burden — Stage IV indicates distant metastasis was confirmed, which remains the biological record. If you are experiencing new symptoms that may indicate progression or recurrence, our cancer symptoms checklist can help frame those concerns before seeing a provider.
What does T3 N1 M0 mean in cancer staging?
T3 N1 M0 describes a cancer with a larger primary tumor (T3 — specific definition varies by cancer type but generally indicates substantial local invasion), spread to a limited number of regional lymph nodes (N1 — typically 1–3 nodes), and no distant organ spread (M0). In the stage grouping, T3 N1 M0 typically corresponds to Stage IIIA in many cancers. In breast cancer specifically: T3 N1 M0 means a tumor larger than 5 cm with 1–3 positive axillary lymph nodes — Stage IIIA, treated with chemotherapy, surgery, and often radiation. The specific meaning of each T and N number differs between cancer types — always ask your oncologist to clarify the overall stage group (I, II, III, or IV) from your specific TNM designation.
Sources & Further Reading
- NCI — Stages of Cancer
- American Cancer Society — Cancer Staging
- AJCC Cancer Staging Manual 8th Edition
- Amin MB et al. — AJCC Cancer Staging Manual, 8th Edition, 2017
- Cheson BD et al. — Lugano Classification (lymphoma staging), JCO 2014
- NCI SEER Database — 5-year relative survival rates (ACS Cancer Statistics 2024)
- FIGO Staging 2018 updates — gynecologic malignancies
This article is for educational purposes only and does not constitute medical advice. Cancer staging, prognosis, and treatment decisions should be discussed with your oncologist.
Pingback: Cancer Grade: What It Means and Why It Matters for Treatment - Horizon Health Guide
Pingback: Cancer Diagnosis Questions to Ask Your Doctor - Horizon Health Guide
Pingback: Cancer Surgery: Types, Goals, and What to Expect - Horizon Health Guide